HCW Biologics Completes Follow-On Offering to Fund Pipeline

HCW Biologics ( (HCWB) ) just unveiled an update.

On February 17, 2026, HCW Biologics Inc. entered into a securities purchase agreement with a single institutional investor for a follow-on public offering of 2,477,292 units, each comprising a common share or pre-funded warrant plus a common stock warrant, at $0.6055 per unit. The offering, conducted under an effective Form S-1 registration, priced at-the-market under Nasdaq rules and closed on February 19, 2026, generating gross proceeds of approximately $1.5 million before fees.

The company also struck a privately negotiated agreement with the same investor to seek shareholder approval to cut the exercise price of existing warrants on up to 3,020,410 shares from $2.41 to the new $0.6055 level, while the newly issued common stock warrants will only become exercisable upon such approval and will run for five years from that date. HCW Biologics engaged Maxim Group LLC as sole placement agent, paying a 6.9% cash fee plus expenses, and plans to deploy the net proceeds to fund preclinical and clinical development, including trials for lead candidate HCW9302, and for general corporate purposes, underscoring its reliance on equity-linked financing to advance its inflammation-focused pipeline.

The most recent analyst rating on (HCWB) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on HCW Biologics stock, see the HCWB Stock Forecast page.

Spark’s Take on HCWB Stock

According to Spark, TipRanks’ AI Analyst, HCWB is a Neutral.

The score is held down primarily by very weak financial performance (sharp revenue decline, negative gross profit in TTM, persistent cash burn, and negative equity). Technicals also remain unfavorable with price below key longer-term moving averages and negative MACD. Offsetting factors are limited to positive corporate developments (financing/liability settlement to bolster equity and a Phase 1 trial start), which improve near-term positioning but do not yet change the fundamental risk profile.

To see Spark’s full report on HCWB stock, click here.

More about HCW Biologics

HCW Biologics Inc. is a U.S.-based clinical-stage biopharmaceutical company listed on Nasdaq that develops proprietary immunotherapies targeting chronic inflammation, including age-related and senescence-associated diseases. Its lead candidate, HCW9302, emerged from the company’s TOBI platform, while its TRBC technology underpins a pipeline of more than 50 molecules for oncology, autoimmune conditions and quality-of-life indications, alongside two active licensing programs.

The TRBC platform is designed to create multi-functional immune cell stimulators, second-generation checkpoint inhibitors and multi-specific fusion proteins that both activate immune responses and selectively target cancerous or infected cells. HCW Biologics is advancing HCW9302 in a company-sponsored Phase 1 trial for autoimmune disease and preparing three TRBC-based molecules for IND-enabling work in cancer and age-related disorders, aiming to reposition itself as a key player in inflammation-driven therapeutics.

Average Trading Volume: 75,128

Technical Sentiment Signal: Sell

Current Market Cap: $1.97M

Learn more about HCWB stock on TipRanks’ Stock Analysis page.